Do GLP-1 drugs really produce the weight loss everyone claims

Introduction: what Cochrane just actually confirmed

A highly anticipated scientific review of the star drugs

For several years, drugs in the GLP-1 receptor agonist family have made headlines, sometimes hailed as a weight-loss miracle, sometimes suspected of hidden dangers. The Cochrane Collaboration, an organization known for the rigor of its meta-analyses, has published three systematic reviews commissioned by the World Health Organization on tirzepatide, semaglutide, and liraglutide. This fact-check verifies precisely what this data shows, and more importantly, what it does not.

The stakes go beyond mere scientific curiosity: millions of people are already considering or using these treatments, often based on viral testimonials rather than solid clinical data. It is time to separate verified fact from marketing exaggeration.

Why this topic deserves rigorous verification

Social media is full of claims that these drugs melt away pounds effortlessly and without limit. The reality, as documented by Cochrane, is more nuanced, more measured, and ultimately far more interesting for anyone seeking reliable information rather than an advertising slogan.

This fact-check relies exclusively on data published by Cochrane and the randomized clinical trials it analyzed, with no extrapolation or unfounded promises.

Claim 1: tirzepatide causes about 16% body weight loss

What the eight analyzed clinical trials show

Verdict: true, with nuance. The Cochrane review devoted to tirzepatide, marketed notably under the name Zepbound, analyzed eight randomized trials covering more than 6,361 participants. The results show average weight loss of roughly 16% of initial body weight over a period of twelve to eighteen months, one of the highest results observed for this drug class to date.

This impressive figure must, however, be put into context: it is a group average, and individual response varies considerably from person to person depending on metabolism, concurrent diet, and adherence to treatment over time.

Effectiveness that appears to hold over time

A notable fact confirmed by the data: this weight loss was sustained for up to three and a half years among participants who continued treatment, which sets tirzepatide apart from many weight-loss interventions whose effects quickly fade after discontinuation.

This persistence of effect is one of the strongest elements of the review, precisely because it rests on long-term follow-up rather than short-term results easily inflated by a novelty effect.

Claim 2: semaglutide delivers comparable results

Real but slightly lower effectiveness

Verdict: true. The second Cochrane review, covering semaglutide (known under the brand names Ozempic and Wegovy), compiled eighteen clinical trials totaling nearly 27,949 participants, a considerably larger sample than that of tirzepatide. The results show average weight loss of about 11% over a period of 24 to 68 weeks.

This result, though lower than the 16% reported for tirzepatide, remains clinically significant and far exceeds results obtained with conventional non-drug approaches for most patients studied.

More frequent gastrointestinal side effects

The review also notes that semaglutide is associated with more digestive side effects, including nausea, vomiting, and gastrointestinal disorders, compared with the other molecules studied. These side effects, while generally not severe, led a significant number of participants to discontinue treatment during the trials.

The review's authors also note that the effect is sustained for up to two years in patients who continue treatment, a shorter horizon than what has been documented for tirzepatide, due to a lack of longer-term data.

Claim 3: liraglutide is just as effective as the newer molecules

A more modest but still significant result

Verdict: false. Contrary to a claim sometimes circulating online, liraglutide, an older molecule marketed as Saxenda, shows markedly more modest effectiveness than its successors. The Cochrane review, which analyzed twenty-four trials covering 9,937 participants, reports average weight loss of only about 4 to 5%.

This result, while statistically significant compared with a placebo, clearly places liraglutide behind semaglutide and tirzepatide in terms of pure weight-loss effectiveness.

Why this molecule remains relevant nonetheless

Liraglutide remains a valid therapeutic option for certain patients, particularly those who cannot tolerate the newer molecules or who lack access to them due to cost or shortages. Its safety profile, established over a longer period, also offers clinical experience that the newer molecules have not yet accumulated.

This effectiveness hierarchy among the three molecules should guide discussions between patients and healthcare professionals, rather than simple word of mouth or trends on social media.

Claim 4: industry funding skews all the results

A real but not universal funding bias

Verdict: partially true. The authors of the Cochrane reviews themselves note that a significant proportion of the clinical trials analyzed were funded by the manufacturers of the drugs studied, notably Eli Lilly for tirzepatide and Novo Nordisk for semaglutide and liraglutide. This industry funding is a genuine risk factor for bias that it would be dishonest to ignore.

This does not mean the results are fabricated or false: randomized controlled trials remain a rigorous methodology, but transparency about funding sources remains essential for a full critical assessment.

Cochrane's call for independent studies

This is precisely why Cochrane explicitly calls for independent studies, not funded by the pharmaceutical industry, to confirm or refine these results over the long term. This call for independence is itself an important piece of information that much media coverage has glossed over.

Without these independent studies, our collective understanding of the very long-term benefits and risks of these molecules will remain incomplete, particularly regarding use beyond three to five years.

Claim 5: stopping treatment would not change the results

What the data actually suggest about discontinuing treatment

Verdict: false. Although the three Cochrane reviews do not specifically focus on the consequences of stopping treatment as a central axis, the broader scientific literature on these molecules, along with observations made during the follow-up phases of the included trials, strongly suggest that partial weight regain frequently occurs after treatment is discontinued.

This finding reinforces the idea that these drugs should be understood as a long-term management treatment for a chronic condition, rather than as a one-time cure with a permanently secured result.

A reality that changes how the treatment is perceived

This nuance fundamentally changes how the public should view these drugs: not as a temporary shortcut to an aesthetic goal, but as a permanent therapeutic commitment, with all the financial and medical implications that entails for healthcare systems and patients themselves.

This reality is rarely highlighted in promotional campaigns, even though it should be central to any honest discussion between a patient and their doctor before starting such treatment.

Claim 6: these drugs are safe for everyone

Real contraindications and precautions

Verdict: false. The Cochrane reviews and associated regulatory literature note that these molecules are not suitable for all profiles. Personal or family history of certain thyroid cancers, prior pancreatitis, or pregnancy are among the contraindications or precautions flagged by regulatory agencies overseeing tirzepatide, semaglutide, and liraglutide.

This clinical reality confirms that no drug, however effective on paper, is universally safe, and that individual medical evaluation remains essential before any prescription.

The importance of serious medical oversight

The growing use of these molecules outside of strict medical oversight, sometimes through parallel channels or unregulated imports, worries health authorities in several Western countries. This trend exposes patients to avoidable risks that properly supervised clinical trials take care to monitor.

A treatment with scientifically proven effectiveness remains dangerous if used without appropriate medical follow-up, an essential reminder amid the current strong public demand for these products.

Claim 7: Cochrane's results close the scientific debate

A solid review, but not the final word

Verdict: false. Rigorous as these three reviews are, Cochrane itself insists they do not represent an endpoint in research on these molecules. Many questions remain open: very long-term cardiovascular effects, impact on muscle mass in certain patient groups, and still-insufficient direct head-to-head comparisons between the three molecules studied.

Presenting these reviews as a definitive, unchangeable scientific truth would therefore be misleading, even though they currently constitute the most reliable synthesis publicly available on the subject.

Why scientific vigilance must continue

The international scientific community, including researchers independent of industry, will continue monitoring these molecules as their use spreads globally. It is this ongoing vigilance that will make it possible to confirm, refine, or revise current conclusions in the years ahead.

The public would do well to keep this caution in mind rather than treating these results, solid as they currently are, as a scientific verdict carved in stone forever.

Conclusion: what to take away from this fact-check

An overall positive but nuanced assessment

This fact-check confirms that GLP-1 drugs produce real, clinically significant results for weight loss, particularly tirzepatide and semaglutide. These results are corroborated by well-designed randomized trials, rigorously analyzed by Cochrane on behalf of the WHO.

But this positive assessment comes with essential caveats: industry funding of the trials, non-negligible side effects, the likely need for continuous treatment, and data still limited beyond three to four years of use.

The key message for the general public

The lesson from this review is neither blind enthusiasm nor outright rejection, but an informed approach: these drugs work, to a specific and documented degree, for a specific patient profile, under medical supervision, with a clear understanding of the long-term implications.

This is exactly the kind of nuance the public deserves, far from the viral shortcuts and excessive commercial promises that too often circulate around this sensitive topic affecting the health of millions of people.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limits

I am neither a doctor nor a pharmacology researcher, but a columnist who translates public scientific data for a general readership. I have no financial ties to the pharmaceutical industry, and I have never personally tried these molecules.

My work consists of reading publications from recognized sources like Cochrane and faithfully conveying their content, without exaggeration or minimization, while clearly flagging the uncertainties that remain.

What I do not know

I cannot predict the effects of these drugs after ten or twenty years of use, since no such data currently exists. Nor can I offer guidance on any individual case: any treatment decision requires a consultation with a qualified healthcare professional.

My method consists of directly citing the figures published by Cochrane and the underlying clinical trials, without extrapolating beyond what the data allows.

Sources

Primary sources

Cochrane, GLP-1 drugs effective for weight loss but more independent studies needed — June 2026

PubMed, systematic review on tirzepatide for weight management

Secondary sources

PubMed, systematic review on semaglutide and liraglutide for weight management

Cochrane Collaboration, post on GLP-1 receptor agonists — June 2026

World Health Organization, sponsor of the Cochrane reviews on GLP-1 treatments

Nature, scientific resources on obesity treatments